Using Tocilizumab (TCZ), a human IL-6 blockade agent, indicated a reduction in lung lesion opacity, oxygen demand, decrease in C-reactive protein, and normalization of lymphocytes count in 90.5, 75, 84.2, and 52.6% in COVID-19 patients, respectively [27]. Here, CRP is linked to COVID-19.